[Goals of treatment for osteoporosis].
Clinical practice is based on the data obtained in the randomized clinical trials with robust statistical power. Results of meta-analysis including plural randomized trials are also reliable, directly indicating the consistency of the efficacy of the treatment. Osteoporosis, a reduction in bone strength, is a disease of increased fracture risk, leading to enforced morbidity due to chronic pain and skeletal deformity and consequent increase in mortality. Thus, the reduction in fracture risk is just a prerequisite, and the decreases in morbidity and mortality are expected as the further goal of osteoporosis treatment. Evidences have been accumulated to indicate that treatments with amino-bisphosphonates reduce fracture risk, maintain ADL and QOL, and decrease the death rates. Osteoporosis treatment is greatly recommended to improve the general health condition in elderly people.
Nakamura
Toshitaka
T
University of Occupational and Environmental Health, School of Medicine, Department of Orthopedic Surgery.
D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000188:drug therapy* / Q000517:prevention & control; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012306:Risk
D050071:Bone Density Conservation Agents; D004164:Diphosphonates